Avadel Pharmaceuticals (AVDL) Total Current Liabilities (2016 - 2022)
Historic Total Current Liabilities for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to $41.5 million.
- Avadel Pharmaceuticals' Total Current Liabilities rose 13603.23% to $41.5 million in Q3 2022 from the same period last year, while for Sep 2022 it was $41.5 million, marking a year-over-year increase of 13603.23%. This contributed to the annual value of $21.0 million for FY2021, which is 3899.0% up from last year.
- Latest data reveals that Avadel Pharmaceuticals reported Total Current Liabilities of $41.5 million as of Q3 2022, which was up 13603.23% from $46.2 million recorded in Q2 2022.
- Over the past 5 years, Avadel Pharmaceuticals' Total Current Liabilities peaked at $87.2 million during Q1 2018, and registered a low of $9.1 million during Q1 2021.
- Over the past 5 years, Avadel Pharmaceuticals' median Total Current Liabilities value was $32.3 million (recorded in 2020), while the average stood at $34.2 million.
- Its Total Current Liabilities has fluctuated over the past 5 years, first crashed by 7179.61% in 2021, then soared by 38270.83% in 2022.
- Avadel Pharmaceuticals' Total Current Liabilities (Quarter) stood at $38.4 million in 2018, then fell by 6.25% to $36.0 million in 2019, then crashed by 58.01% to $15.1 million in 2020, then skyrocketed by 38.99% to $21.0 million in 2021, then surged by 97.67% to $41.5 million in 2022.
- Its last three reported values are $41.5 million in Q3 2022, $46.2 million for Q2 2022, and $44.0 million during Q1 2022.